Iressa v BSC (Best Supportive Care) in First Line NSCLC
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care
treatment will increase the progression free survival of chemo-naïve, poor performance status
patients, with stage IIIB or IV NSCLC.